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Abstract
Aims Left atrium (LA) dilation is associated with adverse cardiovascular (CV) outcomes. Blood stasis, thrombus formation
and atrial ﬁbrillation may occur, especially in heart failure (HF) patients. It is not known whether preventive antithrombotic
treatment may decrease the incidence of CV events in HF patients with LA enlargement.
We investigated the relationship between LA enlargement and CV outcomes in HF patients and the effect of different anti-
thrombotic treatments.
Methods and results Two-dimensional echocardiography with LA volume index (LAVi) measurement was performed in 1148
patients with systolic HF from the Warfarin versus Aspirin in Reduced Ejection Fraction (WARCEF) trial. Patients were random-
ized to warfarin or aspirin and followed for 3.4 ± 1.7 years. While the primary aim of the trial was a composite of ischaemic
stroke, death, and intracerebral haemorrhage, the present report focuses on the individual CV events, whose incidence was
compared across different LAVi and treatment subgroups.
After adjustment for demographics and clinical covariates, moderate or severe LA enlargement was signiﬁcantly associated
with total death (hazard ratio 1.6 and 2.7, respectively), CV death (HR 1.7 and 3.3), and HF hospitalization (HR 2.3 and 2.6)
but not myocardial infarction (HR 1.0 and 1.4) or ischaemic stroke (1.1 and 1.5). The increased risk was observed in both pa-
tients treated with warfarin or aspirin. In warfarin-treated patients, a time in therapeutic range >60% was associated with
lower event rates, and an interaction between LAVi and time in therapeutic range was observed for death (P = 0.034).
Conclusions In patients with systolic HF, moderate or severe LA enlargement is associated with death and HF hospitalization
despite treatment with antithrombotic medications. The possibility that achieving a more consistent therapeutic level of
anticoagulation may decrease the risk of death requires further investigation.
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Introduction
In the past decades, an enlargement of the left atrium (LA) has
been shown to be associated with unfavourable cardiovascu-
lar (CV) outcomes. LA enlargement has been associated with
increased risk of death,1,2 stroke,2–4 heart failure (HF),5,6 and
development of atrial ﬁbrillation.7–9 These associations have
been established in the general population as well as in pa-
tients with CV diseases. In patients with HF, LA size has been
shown to be a powerful predictor of outcome, providing addi-
tional prognostic information to that provided by left ventric-
ular (LV) systolic and diastolic function.10 LA volume (LAV), the
most accurate echocardiographic measure of LA size, has been
shown to be independently associated with mortality in indi-
viduals with suspected HF from the community,11 inversely as-
sociated with transplant-free survival in patients with dilated
cardiomyopathy,12 and predictive of outcome in patients un-
dergoing cardiac resynchronization therapy.13
The mechanisms underlying the association between LA
size and outcome are not entirely clear. Because the LA di-
lates in response to multiple stimuli (mitral valve disease, ar-
terial hypertension, and any condition increasing the LV ﬁlling
pressures),14–16 LA size may be regarded as an indicator of
the combined effect of these conditions over time, a circum-
stance that may explain in part its association with CV out-
comes. However, LA enlargement also predisposes to
conditions that may directly affect the risk of CV events, es-
pecially those of embolic origin such as ischaemic stroke. LA
enlargement is associated with blood stasis and is a strong
risk factor for the development of atrial ﬁbrillation,7–9 both
conditions that are associated with hypercoagulability and
are especially frequent in HF. Therefore, the use of systemic
anticoagulation in HF patients with LA enlargement could
theoretically decrease in them the risk of embolic
complications.
In the Warfarin versus Aspirin in Reduced Cardiac Ejection
Fraction (WARCEF) trial, warfarin treatment reduced the risk
of ischaemic stroke in patients with systolic HF in sinus
rhythm, although the beneﬁt was offset by an increased fre-
quency of major haemorrhage. No signiﬁcant difference be-
tween warfarin and aspirin treatment was observed for
other CV outcomes.17 In the present report, we analyse the
relationship between LA size and CV events in the WARCEF
cohort and the effect on it of treatment with warfarin or
aspirin.
Methods
Study patients
The details of the WARCEF trial enrollment have been previ-
ously published. Brieﬂy, from October 2002 to January 2010,
a total of 2305 patients were enrolled in the trial (1119 in the
USA and Canada and 1186 in Europe and Argentina) at 168
centres in 11 countries. Eligible patients were 18 years of
age or older and had normal sinus rhythm, no contraindica-
tion to warfarin therapy, and a left ventricular ejection frac-
tion (LVEF) of 35% or less as assessed by quantitative
echocardiography (or a wall motion index of ≤1.2) or by ra-
dionuclide or contrast angiography within 3 months before
randomization.
Patients in any New York Heart Association (NYHA) func-
tional classes were eligible, but patients in NYHA Class I could
account for no more than 20% of the total number of pa-
tients undergoing randomization. Patients who had a clear in-
dication for warfarin or aspirin were not eligible. Patients
were also ineligible if they had a condition that conferred a
high risk of cardiac embolism, such as atrial ﬁbrillation, a me-
chanical cardiac valve, endocarditis, or an intracardiac mobile
or pedunculated thrombus. Planned treatment with a beta-
blocker, an angiotensin-converting enzyme inhibitor, or an
angiotensin-receptor blocker or hydralazine and nitrates
was also a reason for ineligibility, whereas current treatment
with those medications was allowed.
The study complies with the Declaration of Helsinki. Pa-
tients provided informed consent, and the study was ap-
proved by the international review boards and ethics
boards of participating centres.
Study medication
Patients were randomized to antithrombotic treatment with
either adjusted dose-warfarin with target international nor-
malized ratio (INR) of 2.75 (acceptable range between 2.0
and 3.5) or aspirin 325 mg daily in a double-blind, double-
dummy design. The statistical analysis centre fabricated clin-
ically plausible INR results for patients in the aspirin group
and provided these results to the sites, along with the actual
INR results for the patients in the warfarin group, so that all
the patients were treated as if they were receiving active
warfarin.
Treatment for HF was continued and titrated as clinically
indicated, and individual medications usage was recorded.
Left atrium volume determination
All echocardiograms were reinterpreted, blinded to treat-
ment assignment, at a core echocardiography laboratory to
conﬁrm the accuracy of LVEF assessment.18 LAV was then
measured by Simpson’s biplane rule and indexed by body sur-
face area. The LAV index (LAVi) thus obtained was divided
into four categories (normal, mildly, moderately, or severely
dilated) according to the guidelines of the American Society
of Echocardiography.19 The present analysis is based on the
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1148 patients who had the echocardiographic views for LAV
measurement available. A comparison between patients with
and without LAVi information is provided in Supporting Infor-
mation, Table S1.
Follow-up and outcome events
Follow-up was performed monthly by telephone or in person
at the time the blood was obtained for determination of the
INR, to assess adherence to the study drug and to regulate
INR values. A follow-up assessment in person was also con-
ducted quarterly for a clinical evaluation and annually for a
detailed examination.
While the primary outcome of the trial was the time to the
ﬁrst event in a composite end point of ischaemic stroke, in-
tracerebral haemorrhage, or death from any cause, the pres-
ent report focuses on individual CV outcomes, which were
deﬁned as follows.
Stroke was deﬁned as a clinically relevant new lesion de-
tected on computed tomography or magnetic resonance im-
aging or, in its absence, clinical ﬁndings consistent with
clinical stroke and lasting over 24 h.
The diagnosis of myocardial infarction (MI) was based on
two of the following: (i) typical cardiac pain or its equivalent;
(ii) electrocardiogram evidence of acute MI; or (iii) positive
cardiac biomarkers.
Sudden death was deﬁned as (i) death witnessed or occur-
ring within 15 min of observed collapse or new cardiac symp-
toms, without preceding other modes of death, or (ii) death
unwitnessed but known to have occurred in the prior 72 h
in the absence of other modes of death or (iii) patient resus-
citated from cardiac arrest and dying within 24 h or prior to
discharge, in case neurologic function was not restored.
Cardiovascular death included sudden death, documented
ventricular tachycardia or ﬁbrillation, documented
bradyarrhythmia, MI, and circulatory failure.
Hospitalizations for HF during the follow-up were deﬁned
as admissions with typical symptoms; IV diuretics, vasodila-
tor, or inotropic therapy; and at least 24 h of hospital stay.
Statistical analysis
Baseline demographics, clinical characteristics, and various
outcome events by LAV categories were compared using
ANOVA F-tests for continuous variables, χ2 tests for categori-
cal variables, and log-rank tests for time-to-event outcomes.
Univariable and multivariable Cox models were used to as-
sess the independent effect of demographic and clinical vari-
ables on the outcome events of interest. Missing values for
basic covariates were imputed using means for continuous
variables and modal values for categorical variables.
The incidence rates of outcome events stratiﬁed by LAVi
categories were reported. The association between LAVi cat-
egory and each outcome was ﬁrst assessed with univariable
Cox models and then with adjustment for other patient co-
variates, including incident atrial ﬁbrillation.
We further investigated the risk of events stratiﬁed by type
of antithrombotic treatment (aspirin or warfarin). Cox models
were used to evaluate the association between LAVi category
and outcome events separately in patients treated with aspi-
rin or warfarin and also to assess the interaction of LAVi and
treatment type.
We used the same approach to evaluate the possibility
that the interaction between LAVi and warfarin treatment
on outcome risk might be mediated by differences in time
in therapeutic range (TTR). Cox models were used to evaluate
the association between LAVi category and outcome events
separately in patients with TTR ≤60% or >60% and also to as-
sess the interaction of LAVi and TTR.
Results
Patients with and without LAVi information available dif-
fered for some demographic and clinical variables but not
for frequency of outcome events (Supporting Information,
Table S1). The demographics and clinical characteristics of
the study cohort by LAVi category are illustrated in Table 1.
LAVi categories differed by cohort geographic location and
race–ethnicity distribution. Indices of HF severity (NYHA classi-
ﬁcation; LVEF; and use of diuretics, aldosterone blockers, and
beta-blockers) were also signiﬁcantly different across catego-
ries of LAVi, along with peripheral vascular disease and indices
of renal function.
In the 1148 patients of the LAVi cohort, the mean follow-
up time was 3.4 ± 1.7 years, and the total follow-up time
was 3846 patient-years. Overall, 179 patients (15.6%) had
CV death, 105 patients (9.1%) had sudden death, 28 patients
(2.4%) had an MI, 36 (3.1%) suffered an ischaemic stroke, and
229 patients (20.0%) experienced an HF hospitalization. Inci-
dent atrial ﬁbrillation was observed in 127 patients (11.1%;
13.3% in the aspirin group and 8.8% in the warfarin group;
P = 0.017).
Left atrial volume index and outcomes
The incidence rates and adjusted hazard ratios (HRs) of out-
come events stratiﬁed by LAVi category, after adjustment
for pertinent covariates, are reported in Figure 1. Moder-
ately or severely dilated LAVi was signiﬁcantly associated
with total death [HR 1.6, 95% conﬁdence interval (CI) 1.1
to 2.4 and HR 2.7, CI 2.0 to 3.7, respectively], CV death
(HR 1.7, CI 1.1 to 2.8 and HR 3.3, CI 2.2 to 4.9, respec-
tively), and HF hospitalization (HR 2.3, CI 1.5 to 3.3 and
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Table 1 Patient demographics and clinical characteristics by LAVi category
LAVi (mL/m2)
P-value*
Reference range
(≤34)
Mildly abnormal
(35–41)
Moderately abnormal
(42–48)
Severely abnormal
(≥49)
(n = 465) (n = 225) (n = 187) (n = 271)
Location 0.026
Argentina 20/465 (4.3) 6/225 (2.7) 5/187 (2.7) 6/271 (2.2) —
Europe 264/465 (56.8) 117/225 (52.0) 106/187 (56.7) 180/271 (66.4) —
North America 181/465 (38.9) 102/225 (45.3) 76/187 (40.6) 85/271 (31.4) —
Patient characteristics
Age, years 61.2 ± 11.0 60.1 ± 11.7 60.0 ± 11.2 60.9 ± 12.2 0.510
Male sex 369/465 (79.4) 173/225 (76.9) 155/187 (82.9) 220/271 (81.2) 0.445
Race or ethnic group 0.026
Non-Hispanic White 374/465 (80.4) 163/225 (72.4) 147/187 (78.6) 217/271 (80.1) —
Non-Hispanic Black 44/465 (9.5) 43/225 (19.1) 23/187 (12.3) 38/271 (14.0) —
Hispanic 31/465 (6.7) 15/225 (6.7) 11/187 (5.9) 8/271 (3.0) —
Other 16/465 (3.4) 4/225 (1.8) 6/187 (3.2) 8/271 (3.0) —
Height, cm 171.9 ± 9.1 172.3 ± 9.2 171.5 ± 9.6 171.3 ± 8.7 0.659
Weight, kg 83.6 ± 18.9 86.9 ± 17.9 85.9 ± 19.2 86.0 ± 19.3 0.112
Body mass index 28.2 ± 5.8 29.2 ± 5.3 29.1 ± 5.6 29.2 ± 6.2 0.050
Educational level 0.888
<High school 226/464 (48.7) 103/225 (45.8) 83/185 (44.9) 121/271 (44.6) —
High school graduate
or some college
167/464 (36.0) 90/225 (40.0) 72/185 (38.9) 110/271 (40.6) —
College graduate or postgraduate 71/464 (15.3) 32/225 (14.2) 30/185 (16.2) 40/271 (14.8) —
Alcohol consumption 0.072
Current, >2 oz/day 129/465 (27.7) 45/225 (20.0) 42/187 (22.5) 53/271 (19.6) —
Previous, >2 oz/day 96/465 (20.6) 44/225 (19.6) 35/187 (18.7) 49/271 (18.1) —
Never 240/465 (51.6) 136/225 (60.4) 110/187 (58.8) 169/271 (62.4) —
Smoking status 0.153
Current smoker 90/464 (19.4) 33/225 (14.7) 30/186 (16.1) 41/271 (15.1) —
Former smoker 254/464 (54.7) 121/225 (53.8) 91/186 (48.9) 139/271 (51.3) —
Never smoker 120/464 (25.9) 71/225 (31.6) 65/186 (34.9) 91/271 (33.6) —
Clinical characteristics
Heart rate, beats/min 71.8 ± 11.3 72.6 ± 12.3 73.2 ± 13.3 72.2 ± 12.7 0.588
Systolic blood pressure,
mmHg
124.2 ± 17.6 126.7 ± 20.1 123.8 ± 17.5 122.5 ± 17.3 0.074
NYHA classiﬁcation 0.009
I 74/465 (15.9) 26/225 (11.6) 27/187 (14.4) 28/271 (10.3) —
II 266/465 (57.2) 129/225 (57.3) 93/187 (49.7) 143/271 (52.8) —
III 119/465 (25.6) 64/225 (28.4) 64/187 (34.2) 100/271 (36.9) —
IV 6/465 (1.3) 6/225 (2.7) 3/187 (1.6) 0/271 (0.0) —
LV ejection fraction, % 25.6 ± 8.1 24.8 ± 7.0 23.4 ± 6.9 23.0 ± 7.3 <0.001
Distance covered on 6 min walk, m 367.8 ± 143.8 334.4 ± 139.4 357.1 ± 150.0 360.6 ± 137.5 0.053
Pacemaker or deﬁbrillator 121/465 (26.0) 45/225 (20.0) 39/187 (20.9) 72/269 (26.8) 0.164
Medical comorbidities
Atrial ﬁbrillation 12/465 (2.6) 13/225 (5.8) 9/187 (4.8) 13/269 (4.8) 0.176
Diabetes mellitus 140/465 (30.1) 76/225 (33.8) 57/187 (30.5) 78/269 (29.0) 0.694
Hypertension 273/454 (60.1) 143/219 (65.3) 104/183 (56.8) 167/264 (63.3) 0.295
Ischaemic cardiomyopathy 207/465 (44.5) 84/224 (37.5) 77/187 (41.2) 135/269 (50.2) 0.034
Myocardial infarction 231/465 (49.7) 104/225 (46.2) 84/187 (44.9) 131/269 (48.7) 0.666
Peripheral vascular disease 36/465 (7.7) 38/225 (16.9) 11/187 (5.9) 40/271 (14.8) <0.001
Prior stroke or TIA 62/465 (13.3) 37/225 (16.4) 16/187 (8.6) 28/269 (10.4) 0.065
Blood chemistry
Creatinine, mg/dL 1.1 ± 0.3 1.2 ± 0.4 1.1 ± 0.3 1.2 ± 0.3 0.030
eGFR 69.0 ± 20.6 69.0 ± 21.1 71.7 ± 20.5 66.2 ± 21.4 0.050
Haemoglobin, g/dL 14.1 ± 1.4 14.0 ± 1.5 14.1 ± 1.6 13.9 ± 1.7 0.343
Haematocrit, % 41.8 ± 4.0 41.4 ± 4.6 41.9 ± 4.8 41.8 ± 4.8 0.640
Sodium, mEq/L 139.6 ± 3.3 140.1 ± 3.2 139.7 ± 3.2 139.4 ± 3.4 0.157
White blood cell count, ×109/L 7.6 ± 2.1 7.3 ± 2.1 7.4 ± 2.1 7.3 ± 1.9 0.094
Medications
Aspirin or other antiplatelet agent 269/380 (70.8) 128/176 (72.7) 99/138 (71.7) 140/210 (66.7) 0.571
Warfarin or other oral anticoagulant 28/465 (6.0) 24/225 (10.7) 17/187 (9.1) 29/271 (10.7) 0.079
ACE inhibitor or ARB 463/465 (99.6) 221/225 (98.2) 186/187 (99.5) 262/268 (97.8) 0.079
Beta-blocker 412/465 (88.6) 210/225 (93.3) 159/187 (85.0) 255/269 (94.8) 0.001
Aldosterone blocker 148/292 (50.7) 88/141 (62.4) 67/113 (59.3) 104/170 (61.2) 0.049
(Continues)
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HR 2.6, CI 1.8 to 3.6, respectively) but not with MI (HR 1.0,
CI 0.3 to 3.3 and HR 1.4, CI 0.5 to 4.0, respectively) or isch-
aemic stroke (HR 1.5, CI 0.6 to 3.8 and HR 0.8, CI 0.3 to
2.1, respectively).
Effect of antithrombotic treatment
Figure 2 shows the outcome incidence rates by type of anti-
thrombotic treatment (aspirin or warfarin), stratiﬁed by LAVi
category. Incidence rates were similar between aspirin-
treated and warfarin-treated patients. The deleterious effect
on the risk of death of a larger LAVi tended to be stronger in
warfarin-treated than in aspirin-treated patients, but no sig-
niﬁcant interaction between LAVi and treatment type was de-
tected (P = 0.604). No signiﬁcant interaction was observed for
any of the other outcomes as well.
In warfarin-treated patients, TTR was evaluated as possibly
affecting the relationship between LAVi and outcomes. Al-
though a relationship between moderately or severely di-
lated LA and death was observed both in patients with TTR
>60% or ≤60%, a signiﬁcant interaction between TTR and
LAVi category was observed (P = 0.034; Supporting Informa-
tion, Table S2). A trend towards a similar interaction was ob-
served for CV death (P = 0.058), whereas no interaction was
observed for other outcomes.
Discussion
In the present report, we describe how LA enlargement, es-
pecially when of moderate or severe degree, remained signif-
icantly associated with death and HF hospitalization in a
cohort of patients with systolic HF in sinus rhythm who were
treated with currently recommended HF regimen, including
antithrombotic medications. On the other hand, no signiﬁ-
cant association was observed between LA enlargement and
ischaemic stroke or MI.
The role of LA enlargement as a predictor of CV events and
death is well documented in the general population and in
patients with CV disease. The most accredited explanation
for this observation is that LA enlargement, rather than
directly affecting the risk of CV events, may represent an
indicator of the combined effect over time of various condi-
tions (such as hypertension, diabetes, mitral valve disease,
and any condition increasing LV ﬁlling pressures)3,14–16 some
of which are in themselves powerful CV risk factors. However,
LA enlargement may also contribute to CV events in a more
direct fashion, by increasing the propensity for intra-atrial
blood stasis and therefore thrombus formation or by facilitat-
ing the development of atrial ﬁbrillation, an established
source for thrombo-embolic events. These mechanisms may
be even more likely to occur in systolic HF, a condition that
is known to be associated in itself with blood hypercoagula-
bility20 and risk of atrial ﬁbrillation development.7–9 As a con-
sequence, LA enlargement in HF might be associated with an
increased frequency of events of embolic origin, which would
make the use of antithrombotic drugs, and especially sys-
temic anticoagulation, an appealing preventive choice. In a
previous meta-analysis on 1157 patients with HF, LA area
was also associated with mortality, but the antithrombotic
treatment was not reported.10 Our present observation of a
persisting increase in CV risk associated with LA enlargement
despite treatment with antithrombotic medications seems to
suggest that LA enlargement may in fact be a risk indicator,
rather than an actual embolic source, in patients with systolic
HF. These results were observed after adjustment for inci-
dent atrial ﬁbrillation, which allowed a better assessment of
the risk of embolic events directly related to LA enlargement,
rather than to the more frequent development of atrial ﬁbril-
lation secondary to it. Moreover, warfarin treatment did not
seem to decrease the risk of events in comparison with aspi-
rin treatment, as would have been conceivable in the case of
an embolic mechanism being frequently at play. An alterna-
tive explanation of this latter ﬁnding might be that an ade-
quate TTR was not uniformly achieved in warfarin-treated
patients, thus conceivably reducing the treatment effect on
embolic events. An adequate TTR (>60%) was achieved in
only 53.3% of patients, which may have diluted the effect
of warfarin treatment on the results. A signiﬁcant interaction
Table 1 (continued)
LAVi (mL/m2)
P-value*
Reference range
(≤34)
Mildly abnormal
(35–41)
Moderately abnormal
(42–48)
Severely abnormal
(≥49)
(n = 465) (n = 225) (n = 187) (n = 271)
Nitrate 100/464 (21.6) 64/225 (28.4) 42/187 (22.5) 72/269 (26.8) 0.155
Calcium-channel blocker 41/465 (8.8) 25/225 (11.1) 13/187 (7.0) 24/268 (9.0) 0.531
Diuretic 350/465 (75.3) 194/225 (86.2) 161/187 (86.1) 243/269 (90.3) <0.001
Statin 292/360 (81.1) 142/170 (83.5) 103/126 (81.7) 162/209 (77.5) 0.499
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular ﬁltration rate; LAVi, left atrial
volume index; LV, left ventricular; NYHA, New York Heart Association; TIA, transient ischaemic attack.
Denominators may vary due to missing information.
*P-values were calculated using ANOVA F-test for continuous variables and χ2 test for categorical variables.
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Figure 1 Outcome incidence rates by category of left atrial volume index (LAVi). CI, conﬁdence interval; CV, cardiovascular; HFH, heart failure hospi-
talization; HR, hazard ratio; MI, myocardial infarction.
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between LAVi and TTR on the risk of death was indeed ob-
served, and a non-signiﬁcant trend was observed for CV
death. This observation raises the question of whether
achieving a better TTR might have ampliﬁed the observed
treatment differences; also, it opens the ﬁeld to the
possibility that the use of novel oral anticoagulants, such as
factor X inhibitors, might achieve a more consistent
anticoagulation level and affect the association between LA
enlargement and CV events to a greater extent than what
was observed for warfarin in WARCEF. Testing novel
Figure 2 Outcome incidence rates by antithrombotic treatment type, stratiﬁed by left atrial volume index (LAVi) category. Abbreviations are as in
Figure 1.
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anticoagulants in this setting, by analogy with what is known
about their effect on thrombo-embolic event in patients with
atrial ﬁbrillation, may provide new insights on preventing CV
events in patients with systolic HF and LA enlargement.
Surprisingly, no signiﬁcant association was observed be-
tween LA enlargement and events of possibly embolic mech-
anism, such as MI and, especially, ischaemic stroke. This lack
of association may have been driven in part by the low num-
ber of such events, which conﬁrms how these adverse out-
comes are infrequent in systolic HF patients in sinus
rhythm treated with currently recommended medical regi-
men, including an antithrombotic medication. Also, no dif-
ference in efﬁcacy was observed in this regard between
warfarin and aspirin. In the main results of WARCEF, warfa-
rin signiﬁcantly reduced the risk of ischaemic stroke com-
pared with aspirin, although the beneﬁt was offset by an
increase in major haemorrhagic events.17 The lack of a sim-
ilar beneﬁcial effect of warfarin when LA enlargement is fac-
tored into the results seems to again suggest that most
strokes in patients with moderate or severe LA enlargement
may not have originated from an embolic mechanism; how-
ever, given the overall small number of strokes, this consid-
eration should be regarded as hypothesis-generating rather
than as a ﬁrm conclusion. It should also be noted that
13.3% of patients in the aspirin-treated group developed
atrial ﬁbrillation during follow-up and were switched to war-
farin treatment, which may have reduced the difference in
treatment effect between warfarin and aspirin in the
intention-to-treat analysis.
Our study has some limitations. Approximately half of the
original WARCEF cohort had adequate information on LAVi.
This smaller sample size may have decreased the ability to
detect signiﬁcant associations between LA enlargement and
low-frequency events such as ischaemic stroke and MI. On
the other hand, the central interpretation of the echocardio-
grams assured the standardization of the assessment of LAVi.
As per WARCEF protocol, only patients with systolic HF (LVEF
<35%) were included in the study; therefore, the relationship
between LA size and outcomes in patient with diastolic HF
could not be investigated. Finally, the study represents a post
hoc analysis involving multiple comparisons from a trial that
was not originally designed to evaluate the relationship be-
tween LA size and outcome; therefore, its results should be
regarded as exploratory.
In conclusion, LA enlargement, especially when of moderate
or severe degree, remains associated with death and HF hospi-
talization in patients with systolic HF treated with currently rec-
ommended medical regimen and antithrombotic medications.
However, our data provide initial evidence that treatment with
systemic anticoagulation may decrease mortality in patients
with moderate or severe LA enlargement, provided an ade-
quate level of anticoagulation is achieved. The possibility that
maintaining a consistent therapeutic level of anticoagulation,
whether by higher TTR during warfarin treatment or by using
newer oral anticoagulants, may prevent a fraction of CV events
in patients with LA enlargement remains to be tested.
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